SCHEMBL4779015

SCHEMBL4779015

O=C(NCc1ccc(Cl)c(Cl)c1)Nc1nc(CCl)ns1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.48
AURKA O14965 1/20 0.48
DYRK3 O43781 1/20 0.48
ROCK2 O75116 1/20 0.48
PRKD3 O94806 1/20 0.48
PRKCG P05129 1/20 0.48
PRKACA P17612 1/20 0.48
RPS6KB1 P23443 1/20 0.48
MARK3 P27448 1/20 0.48
AKT1 P31749 1/20 0.48
CSNK1D P48730 1/20 0.48
CLK2 P49760 1/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
RPS6KA3 P51812 1/20 0.48
PRKX P51817 1/20 0.48
LIMK1 P53667 1/20 0.48
CSNK2A1 P68400 1/20 0.48
CSNK1G2 P78368 1/20 0.48
CDK5 Q00535 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778621 0.82 MAPK1 (0.48) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL353431 0.81 ROCK2 (0.55) MAPK1AURKAROCK2ROCK1AURKB
SCHEMBL4777318 0.80 MEN1 (0.44) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL353663 0.79 KMT2A (0.51) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL355374 0.77 ALDH1A1 (0.37) ROCK2ROCK1MEN1KMT2AALDH1A1
SCHEMBL4782324 0.76 LMNA (0.39) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL24575982 0.74 TSHR (0.71) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL4777145 0.74 SCD (0.51) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL354603 0.74 ROCK1 (0.50) MAPK1AURKADYRK3ROCK2PRKD3
SCHEMBL353480 0.73 ROCK1 (0.49) MAPK1AURKADYRK3ROCK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US disclosed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US disclosed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207703-A1 Antibacterial heterocyclic ureas UMPS, UROD, UGP2 MAPK1 3644/4885AURKA 1196/4885DYRK3 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.